Module 1 Webcast (2018): Core Urology - Trauma

Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.

The purpose of the Life Long Learning Prep Course: A Focused Review is to prepare attendees for the ABU knowledge assessment. This course will be practice-focused and will offer practical and clinically-specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the knowledge assessment. The course will model the changes to the ABU exam by covering Core/General Urology on the first day followed by Module 1: Oncology, Urinary Diversion and Adrenal on the second day.

Sample multiple choice practice questions as well as case-based discussions and debates will be utilized to prepare attendees for the upcoming knowledge assessment. For more information on the changes to the exam, please visit www.abu.org/recertification.

Target Audience

  • Urologists

Learning Objectives

CORE UROLOGY

At the conclusion of this activity, participants will be able to:

  1. Review generally accepted urological practices for superior patient care.
  2. Discuss a core knowledge of urology necessary for taking the Knowledge Assessment.
  3. Examine the most recent changes and additions to the AUA guidelines.

MODULE 1: ONCOLOGY, URINARY DIVERSION AND ADRENAL

At the conclusion of this activity, participants will be able to:

  1. Discuss the appropriate indications for and use diagnostic tests in the management of urologic cancers.
  2. Enhance ability to make guideline-based decisions regarding management of common urologic cancers.
  3. Recognize and execute appropriate measures to prevent and manage complications resulting for management intervention for urologic cancers.
  4. Develop and employ a disease stage appropriate surveillance schedule during post management follow-up of urologic cancers.
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
Course opens: 
09/19/2018
Course expires: 
09/19/2021
Rating: 
0

CORE UROLOGY

Exam Overview and Test Taking Logistics: Gerald H. Jordan, MD                                  
General Cancer 1 (Localized/Advanced Prostate, Localized Kidney): Mark L. Gonzalgo, MD, PhD
General Cancer 2 (Bladder, Upper Tract TCC, Advanced Kidney): Siamak Daneshmand, MD
Medical Urology (Hypertension, Fluids and Electrolytes, Nephrology): Sarah Elfering, MD
Trauma: Jay Simhan, MD
Geriatric Urology: Deborah J. Lightner, MD
Complications of Urologic Surgery: Jay D. Raman, MD
Endocrine: Daniel H. Williams, IV, MD & Sarah Elfering, MD
Stones (Not Metabolic Stones): Mantu Gupta, MD
Prostate Evaluation/Biopsy: Jay D. Raman, MD
Infection: Robert J. Evans, MD, FACS
Radiology/ Radiation Safety: Timothy D. Averch, MD
Office Based Practice and Guidelines: Deborah J. Lightner, MD

MODULE 1: ONCOLOGY, URINARY DIVERSION AND ADRENAL

Upper Tract Tumors/Urinary Diversion: Christopher J. Weight, MD
Prostate Cancer – Localized: Mark L. Gonzalgo, MD, PhD
Testicular Cancer:  Christopher J. Weight, MD
Penile/Urethral Cancer: Siamak Daneshmand, MD
Urothelial Bladder Cancer: Siamak Daneshmand, MD
Adrenal: Mohamad E. Allaf, MD
Kidney Cancer: Mohamad E. Allaf, MD
Prostate Cancer – Advanced: Mark L. Gonzalgo, MD, PhD
Mock Multiple Choice Exam and Review: All Faculty

 

COURSE DIRECTOR

Timothy Averch, MD, FACS: Bard Urologic: Consultant or Advisor, Meeting Participant or Lecturer; Cook Urological, Inc: Consultant or Advisor; Canadian Journal of Urology: Health Publishing; Journal of Endourology: Health Publishing; Journal of Urology: Health Publishing
Daniel H. Williams, IV, MD: Nothing to disclose

FACULTY

Mohamad E. Allaf, MD: Nothing to disclose             
Nelson E. Bennett Jr., MD: Coloplast: Meeting Participant or Lecturer; AMS: Meeting Participant or Lecturer, Scientific Study or Trial; Boston Scientific: Consultant or Advisor; Endo: Meeting Participant or Lecturer; Coloplast: Consultant or Advisor
Sam B. Bhayani, MD: Intuitive Surgical: Meeting Participant or Lecturer; conmed: Consultant or Advisor, Investment Interest; intuitive: Consultant or Advisor , Consultant or Advisor
Benjamin M. Brucker, MD: Allergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sophiris bio inc.: Scientific Study or Trial; Cook myosite: Scientific Study or Trial; Covance: Scientific Study or Trial; Conti Watson : Consultant or Advisor; Avadel: Consultant or Advisor; Serenity: Consultant or Advisor
Christopher J. Chermansky, MD: Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Contura: Scientific Study or Trial; Allergan: Meeting Participant or Lecturer; Cook Myosite: Scientific Study or Trial; Coulter Foundation Grant through Univ of Pitt School of Engineering: Scientific Study or Trial; Allergan: Scientific Study or Trial , Scientific Study or Trial
Siamak Daneshmand, MD: Endo: Meeting Participant or Lecturer; Cubist: Meeting Participant or Lecturer; Photocure: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Taris: Consultant or Advisor; Pacific Edge: Consultant or Advisor     
Sarah Elfering, MD: Nothing to disclose
Robert J. Evans, MD, FACS: Interstitial Cystitis Association: Leadership Position; allergan: Scientific Study or Trial; Afferent: Meeting Participant or Lecturer; urigen: Investment Interest; allergan: Scientific Study or Trial; TARIS: Scientific Study or Trial; Astellas: Meeting Participant or Lecturer; afferent: Scientific Study or Trial; medtronic: Meeting Participant or Lecturer; GTX: Consultant or Advisor; aquinox: Consultant or Advisor, Scientific Study or Trial
Mark L. Gonzalgo, MD, PhD: Nothing to disclose
Mantu Gupta, MD: Cook Urological: Meeting Participant or Lecturer; Boston Scientific: Meeting Participant or Lecturer; Olympus: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Stephen V. Jackman, MD: Nothing to disclose
Deborah J. Lightner, MD: AUA: Health Publishing; Urology/Elsevier: Health Publishing; Neurourology-urodynamics: Health Publishing
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; MDx Health: Scientific Study or Trial; Urogen Pharma: Consultant or Advisor, Scientific Study or Trial
David Shin, MD: Boston Scientific: Meeting Participant or Lecturer; Vivus: Scientific Study or Trial; Endo Pharmaceuticals: Meeting Participant or Lecturer; Society for the Study of Male Reproduction: Leadership Position; Antares Pharm: Consultant or Advisor
Jay Simhan, MD: Boston Scientific : Meeting Participant or Lecturer; Coloplast: Meeting Participant or Lecturer
John T. Stoffel, MD: Uroplasty: Scientific Study or Trial; PCORI: Scientific Study or Trial; Journal of urology: Leadership Position; Department of Defense: Scientific Study or Trial; Ipsen: Scientific Study or Trial
Christopher J. Weight, MD: Precision Health Economics: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Urogen: Scientific Study or Trial; Abbott Molecular: Meeting Participant or Lecturer

 

PDF iconEDUCATION COUNCIL DISCLOSURES

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 0.75 hours

Release Date: September, 2018
Expiration Date: September, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
Please login or register to take this course.